These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
175 related items for PubMed ID: 16825030
1. Novel dosage forms and regimens for sevelamer-based phosphate binders. Duggal A, Hanus M, Zhorov E, Dagher R, Plone MA, Goldberg J, Burke SK. J Ren Nutr; 2006 Jul; 16(3):248-52. PubMed ID: 16825030 [Abstract] [Full Text] [Related]
2. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S. Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256 [Abstract] [Full Text] [Related]
3. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Sturtevant JM, Hawley CM, Reiger K, Johnson DW, Campbell SB, Burke JR, Bofinger A, Isbel NM. Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645 [Abstract] [Full Text] [Related]
4. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. Fischer D, Cline K, Plone MA, Dillon M, Burke SK, Blair AT. Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217 [Abstract] [Full Text] [Related]
5. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212 [Abstract] [Full Text] [Related]
6. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia? Ouellet G, Cardinal H, Mailhot M, Ste-Marie LG, Roy L. Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539 [Abstract] [Full Text] [Related]
7. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Wilkes BM, Reiner D, Kern M, Burke S. Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112 [Abstract] [Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
9. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045 [Abstract] [Full Text] [Related]
10. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH]. Sato M, Fukazawa S, Yasuda T, Akatsuka T, Tozawa S, Niida Y, Hashimoto N, Mochizuki T, Koike T. Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625 [Abstract] [Full Text] [Related]
11. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pai AB, Shepler BM. Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463 [Abstract] [Full Text] [Related]
12. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia. Pai AB, Smeeding JE, Brook RA. Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243 [Abstract] [Full Text] [Related]
14. Calcium-based phosphate binders are appropriate in chronic renal failure. Friedman EA. Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276 [Abstract] [Full Text] [Related]
15. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M. Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475 [Abstract] [Full Text] [Related]
16. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. Pagé D, Knoll G. Adv Perit Dial; 2005 Oct; 21():185-7. PubMed ID: 16686315 [Abstract] [Full Text] [Related]
17. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels]. Fukushima N, Nagano N. Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065 [Abstract] [Full Text] [Related]
18. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis]. Hashimoto N, Miyata M, Sato N, Mochizuki T, Koike T. Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626 [Abstract] [Full Text] [Related]
19. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis. Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160 [Abstract] [Full Text] [Related]